Skip to main content
NCBI home page
Sarcoma logoLink to Sarcoma
. 1997 Dec;1(3-4):123–130. doi: 10.1080/13577149778191

Metastatic Osteosarcoma: A Review of Current Issues in Systemic Treatment

Vivien Bramwell 1,✉
PMCID: PMC2395366  PMID: 18521213

Abstract

Purpose. Original articles and abstracts published between January 1991 and January 1997 were selected according to specified criteria and reviewed to provide answers to five interesting questions about the systemic treatment of metastatic osteosarcoma.

Results.

(1) In patients with metastatic disease at presentation, what is the outcome after intensive multi-agent chemotherapy?

Historically, survival has been poor, but may be improving with the use of ifosfamide-containing regimens.

(2) Can response to new agents be evaluated better in patients who have received no previous chemotherapy?

Based on limited data, this is probably true.

(3) Is the response to neo-adjuvant chemotherapy, as determined by histopathology, similar for the primary tumor and synchronous pulmonary metastases?

With intensive multi-agent chemotherapy, good histological response rates are in the range 70–90% for both groups.

(4) What is the outcome, after intensive combined modality treatment with chemotherapy and surgery, in patients relapsing with metastases after previous adjuvant chemotherapy, and what are the important prognostic factors?

Outcome is highly variable, but 5-year survival ranges between 25 and 50% and a good outcome is more likely if recurrent disease is limited to resectable lung metastases.

(5) Can a biological agent (L-MTP-PE) prolong the time to relapse in patients with resected metastatic osteosarcoma?

Preliminary data suggest that this is possible, but more studies are required.

Full Text

The Full Text of this article is available as a PDF (540.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacci G., Mercuri M., Briccoli A., Ferrari S., Bertoni F., Donati D., Monti C., Zanoni A., Forni C., Manfrini M. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 1997 Jan 15;79(2):245–254. [PubMed] [Google Scholar]
  2. Bramwell V. H. The role of chemotherapy in osteogenic sarcoma. Crit Rev Oncol Hematol. 1995 Aug;20(1-2):61–85. doi: 10.1016/1040-8428(94)00145-j. [DOI] [PubMed] [Google Scholar]
  3. Goorin A. M., Shuster J. J., Baker A., Horowitz M. E., Meyer W. H., Link M. P. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991 Apr;9(4):600–605. doi: 10.1200/JCO.1991.9.4.600. [DOI] [PubMed] [Google Scholar]
  4. Harris M. B., Cantor A. B., Goorin A. M., Shochat S. J., Ayala A. G., Ferguson W. S., Holbrook T., Link M. P. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995 Feb;24(2):87–92. doi: 10.1002/mpo.2950240205. [DOI] [PubMed] [Google Scholar]
  5. Kleinerman E. S. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug;9(4):927–938. [PubMed] [Google Scholar]
  6. Kleinerman E. S., Jia S. F., Griffin J., Seibel N. L., Benjamin R. S., Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992 Aug;10(8):1310–1316. doi: 10.1200/JCO.1992.10.8.1310. [DOI] [PubMed] [Google Scholar]
  7. Kleinerman E. S., Raymond A. K., Bucana C. D., Jaffe N., Harris M. B., Krakoff I. H., Benjamin R., Fidler I. J. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992;34(4):211–220. doi: 10.1007/BF01741788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kleinerman E. S., Snyder J. S., Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991 Feb;9(2):259–267. doi: 10.1200/JCO.1991.9.2.259. [DOI] [PubMed] [Google Scholar]
  9. MacEwen E. G., Kurzman I. D., Rosenthal R. C., Smith B. W., Manley P. A., Roush J. K., Howard P. E. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989 Jun 21;81(12):935–938. doi: 10.1093/jnci/81.12.935. [DOI] [PubMed] [Google Scholar]
  10. Marina N. M., Pratt C. B., Rao B. N., Shema S. J., Meyer W. H. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer. 1992 Dec 1;70(11):2722–2727. doi: 10.1002/1097-0142(19921201)70:11<2722::aid-cncr2820701125>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  11. Meyers P. A., Heller G., Healey J. H., Huvos A., Applewhite A., Sun M., LaQuaglia M. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993 Mar;11(3):449–453. doi: 10.1200/JCO.1993.11.3.449. [DOI] [PubMed] [Google Scholar]
  12. Patel S. R., Papadopoulos N. E., Plager C., Linke K. A., Moseley S. H., Spirindonidis C. H., Benjamin R. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer. 1996 Aug 15;78(4):741–744. doi: 10.1002/(SICI)1097-0142(19960815)78:4<741::AID-CNCR8>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  13. Rosen G., Marcove R. C., Huvos A. G., Caparros B. I., Lane J. M., Nirenberg A., Cacavio A., Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106 (Suppl):55–67. doi: 10.1007/BF00625054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Saeter G., Høie J., Stenwig A. E., Johansson A. K., Hannisdal E., Solheim O. P. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995 Mar 1;75(5):1084–1093. doi: 10.1002/1097-0142(19950301)75:5<1084::aid-cncr2820750506>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  15. Tabone M. D., Kalifa C., Rodary C., Raquin M., Valteau-Couanet D., Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994 Dec;12(12):2614–2620. doi: 10.1200/JCO.1994.12.12.2614. [DOI] [PubMed] [Google Scholar]
  16. Ward W. G., Mikaelian K., Dorey F., Mirra J. M., Sassoon A., Holmes E. C., Eilber F. R., Eckardt J. J. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994 Sep;12(9):1849–1858. doi: 10.1200/JCO.1994.12.9.1849. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES